Owen B. McManus
Research Subjects
Owen B. McManus has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Graham T. Dempsey
Quiver Bioscience, Cambridge, MA, United States
4 shared publicationsLuis A. Williams
Quiver Bioscience, Cambridge, MA, United States
4 shared publicationsChristopher A. Werley
Quiver Bioscience, Cambridge, MA, United States
3 shared publicationsAdam Barnett
Quiver Bioscience, Cambridge, MA, United States
2 shared publicationsAdam E. Cohen
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, United States
2 shared publicationsAmy E. Elder
Quiver Bioscience, Cambridge, MA, United States
2 shared publications
Latest Publications
- 14 November 2023
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (4) , 922-940
A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology
Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. We present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC. Osteoarthritis-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo. To measure the effect of OA-SPARC on neural firing in a scalable format, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell and single action potential resolution and a throughput of up to 500,000 neurons per day. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology. We screened ∼3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including ion channel modulators and other mechanisms including MEK inhibitors and tyrosine kinase modulators. Our results suggest that the Raf-MEK-ERK axis in DRG neurons may integrate the inputs from multiple upstream inflammatory mediators found in osteoarthritis patient joints, and MAPK pathway activation in DRG neurons may contribute to chronic pain in patients with osteoarthritis.
- 14 November 2023
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (4) , 922-940
A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology
Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. We present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC. Osteoarthritis-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo. To measure the effect of OA-SPARC on neural firing in a scalable format, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell and single action potential resolution and a throughput of up to 500,000 neurons per day. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology. We screened ∼3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including ion channel modulators and other mechanisms including MEK inhibitors and tyrosine kinase modulators. Our results suggest that the Raf-MEK-ERK axis in DRG neurons may integrate the inputs from multiple upstream inflammatory mediators found in osteoarthritis patient joints, and MAPK pathway activation in DRG neurons may contribute to chronic pain in patients with osteoarthritis.
- Open Access
A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology
Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. Here, we present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC . OA-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo . To measure the effect of OA-SPARC on neural firing in a scalable format for drug discovery, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell resolution and a throughput of up to 500,000 neurons per day, with patch clamp-like single action potential resolution. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology with different mechanisms of action. We screened ~3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of both functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including well-known ion channel modulators as well as less characterized mechanisms including MEK inhibitors and tyrosine kinase modulators, providing validation of the platform for pain drug discovery.
Open AccessA phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology
Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. Here, we present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC . OA-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo . To measure the effect of OA-SPARC on neural firing in a scalable format for drug discovery, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell resolution and a throughput of up to 500,000 neurons per day, with patch clamp-like single action potential resolution. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology with different mechanisms of action. We screened ~3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of both functional OA-SPARC phenotype rescue and orthogonal “off-target” effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including well-known ion channel modulators as well as less characterized mechanisms including MEK inhibitors and tyrosine kinase modulators, providing validation of the platform for pain drug discovery.
- 14 April 2022
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 43 (5) , 392-405
‘Channeling’ therapeutic discovery for epileptic encephalopathy through iPSC technologies
- 14 April 2022
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 43 (5) , 392-405
‘Channeling’ therapeutic discovery for epileptic encephalopathy through iPSC technologies
- Open Access
- 1 September 2017
- Published by Wiley in Current Protocols in Pharmacology
- Vol. 78 (1) , 11.20.1-11.20.24
All‐Optical Electrophysiology for Disease Modeling and Pharmacological Characterization of Neurons
A key challenge for establishing a phenotypic screen for neuronal excitability is measurement of membrane potential changes with high throughput and accuracy. Most approaches for probing excitability rely on low‐throughput, invasive methods or lack cell‐specific information. These limitations stimulated the development of novel strategies for characterizing the electrical properties of cultured neurons. Among these was the development of optogenetic technologies (Optopatch) that allow for stimulation and recording of membrane voltage signals from cultured neurons with single‐cell sensitivity and millisecond temporal resolution. Neuronal activity is elicited using blue light activation of the channelrhodopsin variant ‘CheRiff’. Action potentials and synaptic signals are measured with ‘QuasAr’, a rapid and sensitive voltage‐indicating protein with near‐infrared fluorescence that scales proportionately with transmembrane potential. This integrated technology of optical stimulation and recording of electrical signals enables investigation of neuronal electrical function with unprecedented scale and precision. © 2017 by John Wiley & Sons, Inc.
- 1 September 2017
- Published by Wiley in Current Protocols in Pharmacology
- Vol. 78 (1) , 11.20.1-11.20.24
Open AccessAll‐Optical Electrophysiology for Disease Modeling and Pharmacological Characterization of Neurons
A key challenge for establishing a phenotypic screen for neuronal excitability is measurement of membrane potential changes with high throughput and accuracy. Most approaches for probing excitability rely on low‐throughput, invasive methods or lack cell‐specific information. These limitations stimulated the development of novel strategies for characterizing the electrical properties of cultured neurons. Among these was the development of optogenetic technologies (Optopatch) that allow for stimulation and recording of membrane voltage signals from cultured neurons with single‐cell sensitivity and millisecond temporal resolution. Neuronal activity is elicited using blue light activation of the channelrhodopsin variant ‘CheRiff’. Action potentials and synaptic signals are measured with ‘QuasAr’, a rapid and sensitive voltage‐indicating protein with near‐infrared fluorescence that scales proportionately with transmembrane potential. This integrated technology of optical stimulation and recording of electrical signals enables investigation of neuronal electrical function with unprecedented scale and precision. © 2017 by John Wiley & Sons, Inc.
- 1 December 1995
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 58 (12) , 1822-1828
L-735,334, a Novel Sesquiterpenoid Potassium Channel-Agonist from Trichoderma virens
Note: In lieu of an abstract, this is the article's first page.
- 1 December 1995
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 58 (12) , 1822-1828
L-735,334, a Novel Sesquiterpenoid Potassium Channel-Agonist from Trichoderma virens
Note: In lieu of an abstract, this is the article's first page.